Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.72 |
| ▸ | MAPT | P10636 | 4/20 | 0.72 |
| ▸ | MAOA | P21397 | 2/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | CASP3 | P42574 | 1/20 | 0.72 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.72 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.72 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.72 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | BCHE | P06276 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.64 |
| ▸ | RELA | Q04206 | 1/20 | 0.64 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.61 |
| ▸ | ACHE | P22303 | 1/20 | 0.61 |
| ▸ | BACE1 | P56817 | 1/20 | 0.61 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14692575 | 1.00 | MAOB (0.72) | MAOBMAPTMAOACYP2C19CYP2D6 | |
| SCHEMBL30504733 | 0.95 | F3 (0.71) | MAOBMAPTMAOACYP2C19CYP2D6 | |
| SCHEMBL30504730 | 0.88 | ABCG2 (0.78) | MAPTCXCL12ABCG2MEN1TNFRSF1A | |
| SCHEMBL31448615 | 0.87 | PTGS1 (0.73) | MAOBMAPTMAOACYP2C19CXCL12 | |
| SCHEMBL5138843 | 0.87 | MAPT (0.67) | MAOBMAPTMAOACYP2C19CYP2D6 | |
| SCHEMBL5138841 | 0.87 | MAPT (0.67) | MAOBMAPTMAOACYP2C19CYP2D6 | |
| SCHEMBL30744137 | 0.87 | MAPT (0.67) | MAOBMAPTMAOACYP2C19CYP2D6 | |
| SCHEMBL30504728 | 0.87 | ABCG2 (0.83) | MAOBMAPTMAOACYP2C19CYP2D6 | |
| SCHEMBL30504738 | 0.86 | ABCG2 (0.76) | MAOBMAPTMAOACYP2C19CYP2D6 | |
| SCHEMBL4773931 | 0.85 | ABCG2 (0.72) | MAOBMAPTMAOACYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9085520-B2 | Composition for treating diabetes and metabolic diseases and a preparation method thereof | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2015-07-21 | — | — | US | disclosed |
| US-20140350304-A1 | COMPOSITION FOR TREATING DIABETES AND METABOLIC DISEASES AND A PREPARATION METHOD THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2014-11-27 | — | — | US | disclosed |
| WO-2013022951-A1 | COMPOSITION FOR TREATING DIABETES AND METABOLIC DISEASES AND A PREPARATION METHOD THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2013-02-14 | — | — | WO | disclosed |
| US-5290951-A | Anticoagulants, antiserotonine agents | ELF SANOFI (FR) | 1994-03-01 | — | — | US | disclosed |
| US-5166416-A | Cardiovascular disorders or antagonist of HT2 receptors | SOCIETE ANONYME: SANOFI (FR) | 1992-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350304-A1 | COMPOSITION FOR TREATING DIABETES AND METABOLIC DISEASES AND A PREPARATION METHOD THEREOF | FABP1, GYS2, CYP7B1 | MAOB 3332/4885MAPT 4070/4885MAOA 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.